Clinical Cancer Research 'Under Review': What Each Status Means

Clinical Cancer Research operates the AACR handling editor model. The handling editor reads the entire paper and evaluates how well the manuscript and described research fit the editorial scope of the journal and its expectations of scientific excellence, importance, and impact on the wider cancer research community. A handling editor at Clinical Cancer Research typically reviews 40 to 60 manuscripts per quarter and spends 30 to 60 minutes on the initial read.

AACR's editorial culture emphasizes fast desk decisions, the 3.8-day median first decision for desk rejections is among the fastest in clinical oncology publishing.

AACR editorial culture at Clinical Cancer Research is decisive: most rejections happen at the handling editor read within the 3.8-day median desk-decision window. Papers that pass the handling editor stage have cleared the steepest filter at AACR's flagship clinical-translational oncology title.

Before the paper reaches external reviewers, an AACR handling editor at Clinical Cancer Research evaluates whether the clinical-translational oncology significance warrants CCR's selective editorial slots. Roughly 75 to 80 percent of submissions are rejected at this stage within the 3.8-day median desk-decision window.

A desk rejection most often means the handling editor concluded that the work would fit better at a sister AACR title (Cancer Research for basic, Molecular Cancer Research for mechanism, Cancer Discovery for top-tier translational) or that the broad-clinical-oncology audience appeal is uncertain.

The AACR editorial office confirms files are complete: manuscript with figures embedded, supplementary information separate, reporting checklists where applicable (CONSORT for clinical trials, STROBE for observational oncology studies, REMARK for tumor-marker prognostic studies, PRISMA for systematic reviews), cover letter directed to the editor, conflict-of-interest declarations, ethics-statement documentation, IRB approvals, trial-registration documentation (AACR requires registered clinical trials), and statistical analysis plan for clinical-trial submissions.

The handling editor reads the paper and evaluates AACR-scope fit, scientific excellence, importance, and impact on the wider cancer research community. AACR's 3.8-day median first decision for desk rejections reflects this fast cadence.

In parallel with the handling editor's primary read, ambiguous-fit papers are discussed at the AACR editor meeting where peer handling editors at sister AACR titles weigh in on whether the paper would fit better at Clinical Cancer Research, Cancer Research, or Cancer Discovery. This editorial-team discussion runs alongside the desk-screen and adds 1 to 3 days to the timeline that is invisible to the author in the portal.

AACR handling editors at Clinical Cancer Research typically invite 2 to 3 external reviewers. The recruitment window can take 5 to 14 days because clinical-translational oncology reviewers with topic-matched expertise are scarce.

Once reviewers agree to review, the typical Clinical Cancer Research peer-review cycle contributes to AACR's 35-day median first-decision-with-review target. AACR uses single-blind peer review across all journals. Reviewers are asked to evaluate scientific excellence, technical rigor, importance, and impact on the wider cancer research community. Reviewer reports for Clinical Cancer Research tend to be thorough; 2000 to 4000 word reports are typical.

After reports return, the handling editor synthesizes them. Only 3.1 percent of AACR journal decisions exceed 60 days per 2024 data. The AACR Manuscript Turnaround Guarantee provides Active Members a full waiver of publication fees if first decision after external peer review exceeds 60 days.

• Rejection within 1 to 3 days: Administrative issue or immediate scope mismatch.

• Rejection within 3 to 7 days: Handling editor desk rejection. Most rejections happen here per the 3.8-day median.

• Still Under Review after 2 weeks: Strong signal. Paper passed the steepest AACR filter.

• Still Under Review after 8 weeks: Reviewer-recruitment or reviewer-report delay. Past 60 days is rare (3.1 percent of decisions), a polite inquiry via the submission portal is appropriate.

• Status changes to "Reports Received": Reports are in; expect a decision within 1 to 2 weeks.

This is the most common anxiety we hear from Clinical Cancer Research authors during the active editorial window. The honest answer: no, 5 weeks at Under Review puts you right at AACR's 35-day median first-decision-with-review target. Reports may already be in editorial synthesis with the handling editor preparing a recommendation. Most reviewer-driven delays come from reviewer-recruitment timing for clinical-translational oncology specialists rather than slow reviews.

If the portal still says Under Review at the 7-week mark, the most likely explanation is that one of the assigned reviewers asked for an extension and the handling editor granted it. This is normal practice at AACR even with the tight median window.

What you should NOT do during the 5-to-7-week window is email the editorial office. AACR handling editors at Clinical Cancer Research are managing 40+ active papers; an inquiry at 5 weeks adds friction without accelerating the timeline.

If your Clinical Cancer Research paper is rejected after review, the natural cascade depends on what the reviewers and handling editor cited:

Cancer Research is the most natural AACR cascade for papers with stronger basic-cancer-biology framing than clinical-translational impact. AACR supports manuscript-transfer within the AACR family with reviewer reports preserved. The transfer process takes 5 to 10 days.

Molecular Cancer Research is the AACR cascade for mechanism-focused cancer biology papers where the molecular mechanism is stronger than the clinical-translational application.

Cancer Discovery is the top-tier AACR cascade for papers with broad translational impact that exceeds CCR's scope.

Journal of Clinical Oncology (JCO) is the ASCO cascade option for clinical-trial papers where the practice-changing impact warrants the JCO bar. ASCO operates independently; reports do not transfer, but JCO editors may recognize AACR reviewer reports informally.

AACR asks reviewers at Clinical Cancer Research to evaluate four things specifically. The table below maps each to actionable preparation.

Across Clinical Cancer Research manuscripts, we see three patterns generate the most consistent reviewer concerns. These are Manusights observations from oncology, biomarker, and clinical-translational manuscripts prepared for AACR and neighboring journals, not hidden AACR decision data.

Clinical-translational significance is often present but under-specified. Many Clinical Cancer Research-targeted drafts have a promising biomarker, mechanism, or cohort result, but the abstract never states what cancer-medicine decision the work could eventually change. Reviewers can then treat the study as descriptive oncology rather than clinical-translational evidence. Stronger manuscripts name the patient population, decision context, endpoint, clinical actionability, and current maturity of the evidence without overstating practice change.

Reporting packages need to be assembled before reviewer comments arrive. CONSORT, REMARK, STROBE, PRISMA, ARRIVE, trial registration, statistical plans, endpoint definitions, and data-availability statements are not clerical details for this journal. They are how reviewers decide whether the translational claim is auditable. The strongest submissions include the checklist logic in the manuscript package and make any exploratory status explicit.

AACR venue mismatch can look like a scientific weakness. A mechanistic cancer-biology manuscript may be excellent but better suited to Cancer Research or Molecular Cancer Research; a broader breakthrough may fit Cancer Discovery; an immunology-specific study may fit Cancer Immunology Research. If the cover letter and Discussion do not explain why Clinical Cancer Research is the right venue, reviewers may treat the manuscript as a narrower oncology report rather than an AACR clinical-translational contribution.

The strongest Clinical Cancer Research response plan links the manuscript, translational relevance statement, clinical table, biomarker assay documentation, endpoint definition, statistical analysis plan, supplementary cohort details, and reporting checklist into one reviewer-readable package.

We often see promising CCR-targeted drafts lose credibility because the biomarker threshold is explained only in the supplement, the endpoint hierarchy is implied rather than stated, the validation cohort is under-described, or the translational relevance statement repeats the abstract without naming a clinical decision. Those are fixable before the decision arrives, and they are much harder to fix under a short revision deadline.

Source limitation: Manusights cannot see private AACR reviewer assignments, queue state, or editor notes. This page combines official AACR guidance, public timing/status information, and Manusights pre-submission review patterns; the ScholarOne record remains the authority for your manuscript.

This page was created from AACR's public author guidance at Aacrjournals source page, AACR Manuscript Turnaround Guarantee documentation, AACR 2024 editorial-speed data (3.8-day median desk decision, 35-day median first decision with peer review, 3.1 percent decisions exceeding 60 days), and Manusights pre-submission review experience with CCR-targeted manuscripts.

For the AACR cancer-research landscape beyond Clinical Cancer Research, start with the Clinical Cancer Research submission guide, Clinical Cancer Research review time guide, Clinical Cancer Research cover letter guide, and Clinical Cancer Research desk-screen guide.

For nearby status pages, compare Cancer Research under review and JAMA Oncology under review. The choice across these titles depends on whether the central contribution is clinical-translational, basic cancer biology, mechanism-focused oncology, top-tier translational oncology, immunology-specific oncology, or practice-changing clinical oncology.

Reviewers at Clinical Cancer Research typically draw from one clinical oncologist and one translational-research expert. Preparing a response template that addresses both perspectives accelerates revision rounds substantially.

For a pre-upload check of your manuscript against the Clinical Cancer Research scientific-excellence-plus-clinical-translational bar before submission, our Clinical Cancer Research pre-submission diagnostic flags the framing weaknesses and reporting-checklist gaps most likely to surface in reviewer reports.